Home / Innere Medizin / Onkologie / Scientific Knowledge Exchange on immunotherapy in lung cancer

Scientific Knowledge Exchange on immunotherapy in lung cancer

In this Scientific Knowledge Exchange Prof. Dr. Solange Peters, Central University Hospital (CHUV) in Lausanne, and OA Dr. Georg Pall, Special Hospital in Wangen, discuss about immunotherapy in lung cancer.

Source: ASCO 2018

The following abstracts are discussed in this SKE:

Jotte RM et al, IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. 

https://meetinglibrary.asco.org/record/165951/abstract 

Lopes G et al: Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. 

https://meetinglibrary.asco.org/record/165950/abstract 

Paz-Ares LG et al: Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). 

https://meetinglibrary.asco.org/record/161684/abstract 

Borghaei H et al: Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227. 

https://meetinglibrary.asco.org/record/160783/abstract 

Socinski MA et al: Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. 

https://meetinglibrary.asco.org/record/160275/abstract

LOGIN

Login

Passwort vergessen?